Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT

被引：0
|
作者：
Bosold, Jonathan
Brauer, Edward
Bril, Vera
Habib, Ali A.
Claeys, Kristl G.
Hussain, Yessar
Gwathmey, Kelly
Sahagian, Gregory
Es-Vicente, Elena Cort
Guptill, Jeffrey
Gelinas, Deborah
Sumbul, Anne
Jimenez, Rosa H.
Hristova, Daniela
Masschaele, Delphine
Mantegazza, Renato
Meisel, Andreas
Attarian, Shahram
机构：
来源：
NEUROLOGY | 2024年 / 103卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S9 / S11
页数：3
相关论文
共 20 条
  • [1] CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT
    Gwathmey, Kelly
    Sahagian, Gregory
    Hussain, Yessar
    Feinberg, Marc
    Habib, Ali
    Skripuletz, Thomas
    Ruck, Tobias
    Rivner, Michael
    Sun, Fang
    Brauer, Edward
    Gelinas, Deborah
    Liu, Li
    Podhorna, Jana
    Mantegazza, Renato
    MUSCLE & NERVE, 2022, 66 : S110 - S110
  • [2] CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT
    Sahagian, Gregory
    Hussain, Yessar
    Feinberg, Marc H.
    Habib, Ali A.
    Skripuletz, Thomas
    Ruck, Tobias
    Brauer, Edward
    Gelinas, Deborah
    Liu, Li
    Podhorna, Jana
    Mantegazza, Renato
    MUSCLE & NERVE, 2022, 65 : S14 - S14
  • [3] CYCLIC AND EVERY-OTHER-WEEK DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: PART A OF ADAPT NXT
    Habib, Ali A.
    Claeys, Kristl G.
    Bril, Vera
    Hussain, Yessar
    Gwathmey, Kelly
    Sahagian, Gregory
    Cortes-Vicente, Elena
    Brauer, Edward
    Gelinas, Deborah
    Sumbul, Anne
    Jimenez, Rosa H.
    Hristova, Daniela
    Masschaele, Delphine
    Mantegazza, Renato
    Meisel, Andreas
    Attarian, Shahram
    MUSCLE & NERVE, 2024, 70 (03) : 541 - 541
  • [4] Fixed dosing (200 meg Q2W) of darbepoetin alfa appears to be as effective as weight-based dosing (3 meg/kg Q2W) in chemotherapy-induced anemia: Results of a clinical trial simulation.
    Jumbe, N
    Bin, Y
    Rovetti, R
    Heatherington, A
    BLOOD, 2002, 100 (11) : 228A - 228A
  • [5] An investigation into the impact of weight on the efficacy of darbepoetin alfa administered as a fixed dose of 200 mcg every 2 weeks (Q2W).
    Heatherington, A
    Gabrilove, J
    Blayney, D
    Tomita, D
    Rossi, G
    BLOOD, 2003, 102 (11) : 11B - 11B
  • [6] Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types
    Zhao, X.
    Shen, J.
    Gopalakrishnan, M.
    Feng, Y.
    Schmidt, B. J.
    Statkevich, P.
    Kelleher, T.
    Rashford, M.
    Ivaturi, V.
    Gobburu, J. V. S.
    Agrawal, S.
    Bello, A.
    Roy, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Every-two-week (Q2W) maintenance dosing with epoetin alfa in anemic patients with cancer receiving chemotherapy: 60,000 U QW to target Hb 12 g/dL, followed by 60,000 U Q2W
    Gregory, SA
    Baltz, B
    Williams, D
    BLOOD, 2004, 104 (11) : 144B - 144B
  • [8] Every-2-week (Q2W) dosing of darbepoetin alfa in patients with anemia of cancer (AOC): Interim analysis of a randomized, controlled study.
    Charu, V
    Belani, CP
    Gill, AN
    Bhatt, M
    Ben-Jacob, A
    Tomita, D
    Katz, D
    Colowick, A
    BLOOD, 2003, 102 (11) : 499A - 499A
  • [9] Dosing With Certolizumab Pegol (CZP) 200 Mg Every 2 Weeks (Q2w) Provides Higher Plasma Trough Concentrations Than 400 Mg Every 4 Weeks (Q4w)
    Lacroix, Brigitte D.
    Parker, Gerald L.
    GASTROENTEROLOGY, 2010, 138 (05) : S163 - S164
  • [10] Initial dosing of epoetin alfa 60,000 U QW followed by Q2W maintenance for anemic patients with cancer receiving chemotherapy
    Baltz, B
    Gregory, SA
    Ehmann, WC
    Williams, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 781S - 781S
12